Effect of Pentoxifylline on Proteinuria

Not Applicable

Conditions: Membranous Nephropathy.
Glomerular Diseases
N00, N01,

Registration Number: IRCT138810273043N1

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 46

Inclusion Criteria

Inclusion Criteria: New cases with biopsy proven Membranous Nephropathy, Initial Random urine protein (mg/dl) > 2 g/day based on 24-hr urine collection

Exclusion Criteria

Pregnancy, Breast feeding, Diabetes Mellitus, History of allergy to Pentoxifylline or any derivatives of methyl xanthenes, Cerebral hemorrhage or Retinal hemorrhage within the past 6 months prior to signing the informed consent form, Congestive heart failure (NYHA functional class III or IV), Uncontrolled hypertension (SBP > 200 mmHg and/or DBP > 110 mmHg), history of unstable angina, myocardial infarction, cerebrovascular accidents, Stroke, Obstructive uropathy, Cirrhosis, Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST > 5 times the upper limit of the normal range, or > 3 times concomitant with signs and symptoms of hepatic failure

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rinary protein excretion. Timepoint: 2 and 6 months after study initiation. Method of measurement: Measurement of Urinary Protein Excretion based on 24-hr urine collection.

Secondary Outcome Measures

Name	Time	Method
Glomerular Filtration Rate (GFR). Timepoint: 2 and 6 months after study initiation. Method of measurement: GFR will be calculated by Cockcroft-Gault formula.